Correlation of lung cancer clinicopathological characteristics with FR+-CTC,ANXA2 and ProGRP

doi:10.3969/j.issn.1673-8640.2022.08.006

Abstract

Abstract:

Objective To investigate the clinical roles of folate receptor positive circulating tumor cells（FR⁺-CTC）,annexin A2（ANXA2） and gastrin-releasing peptide precursor（ProGRP） in lung cancer. Methods A total of 116 lung cancer patients（lung cancer group） and 100 benign lung disease patients（control group） were enrolled. The levels of FR⁺-CTC,ANXA2,ProGRP,cytokeratin 19 fragment（CYFRA21-1）,neuron specific enolase（NSE） and squamous cell carcinoma antigen（SCC-Ag） were determined. Receiver operating characteristic（ROC） curve was used to evaluate the efficacy of each index in the diagnosis of lung cancer. Spearman correlation analysis was used to evaluate the correlation among the indicators. Multivariate Logistic regression analysis was used to evaluate the risk factors of lung cancer. Results The levels of FR⁺-CTC,ANXA2 and ProGRP in lung cancer group were higher than those in control group（P<0.05）. ROC curve results showed that the areas under curves（AUC） of FR⁺-CTC,ANXA2 and ProGRP single and combined determinations were 0.885,0.810,0.696 and 0.935,respectively. Spearman correlation analysis showed that FR⁺-CTC,ANXA2 and ProGRP were positively correlated with CYFRA21-1,NSE and SCC-Ag（P<0.05）. FR⁺-CTC,ANXA2 and ProGRP were increased in patients with smoking history,TNM stage Ⅲ-Ⅳ,tumor diameter ≥5 cm,low differentiation,lymph node metastasis and distant metastasis（P<0.05）. The positivities of FR⁺-CTC,ANXA2 and ProGRP were risk factors for lung cancer [odds ratios（OR） were 1.385,1.774 and 1.823,95% confidence intervals（CI） were 1.187-4.974,1.601-5.075 and 1.677-6.005,respectively]. Conclusions The levels of FR⁺-CTC,ANXA2 and ProGRP are related to the clinicopathological characteristics of lung cancer,and they may be used for the diagnosis and evaluation of lung cancer.

Key words: Folate receptor positive circulating tumor cell, Annexin A2, Gastrin-releasing peptide precursor, Lung cancer

CLC Number:

R446.1

LIU Xingqiang, NING Lifen, LI Lin, CHEN Zhongcheng. Correlation of lung cancer clinicopathological characteristics with FR⁺-CTC,ANXA2 and ProGRP[J]. Laboratory Medicine, 2022, 37(8): 735-740.

Figures/Tables 6

References 18

[1]	陈盔, 王建刚, 韩娉怡. 体检肺癌筛查与健康管理的新模式探讨[J]. 中华健康管理学杂志, 2022, 16(3):199-203.
[2]	SHROFF G S, DE GROOT P M, PAPADIMITRAKOPOULOU V A, et al. Targeted therapy and immunotherapy in the treatment of non-small cell lung cancer[J]. Radiol Clin North Am, 2018, 56(3):485-495. DOI URL
[3]	余芳, 王存吉, 胡亚. 血清微小RNA-296、CC趋化因子受体3表达与非小细胞肺癌复发转移的相关性分析[J]. 中国临床医生杂志, 2021, 49(1):44-48.
[4]	李倩, 郑琪, 马婕群, 等. 叶酸受体阳性循环肿瘤细胞检测的临床研究进展[J]. 标记免疫分析与临床, 2020, 27(2):356-360.
[5]	MA S, LU C C, YANG L Y, et al. ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis[J]. J Exp Clin Cancer Res, 2018, 37(1):183. DOI URL
[6]	李会萍, 郑大勇, 杨帅, 等. 血清胃泌素释放肽前体在小细胞肺癌中的临床价值[J]. 检验医学, 2020, 35(4):310-313.
[7]	赫捷, 李霓, 陈万青, 等. 中国肺癌筛查与早诊早治指南(2021,北京)[J]. 中华肿瘤杂志, 2021, 43(3):243-268.
[8]	杨龙海, 叶波, 魏星, 等. 最新国际肺癌TNM分期标准(第8版)修订稿解读[J]. 中国医刊, 2016, 51(9):22-25.
[9]	苏振华, 章怀成, 江强. 肺癌患者血小板参数与其临床病理特征相关性分析[J]. 检验医学, 2020, 35(5):461-463.
[10]	李雪琴, 陈中文, 金鎏, 等. 2010年至2014年浙江省肿瘤登记地区肺癌发病和死亡情况分析[J]. 中国肿瘤临床, 2018, 45(22):1151-1154.
[11]	CHENG B, XIONG S, LI C, et al. An annual review of the remarkable advances in lung cancer clinical research in 2019[J]. J Thorac Dis, 2020, 12(3):1056-1069. DOI URL
[12]	何雨笑, 鲁继斌. 循环肿瘤细胞对NSCLC浸润深度的评估[J]. 临床肺科杂志, 2020, 25(10):1468-1472.
[13]	CHEN L, PENG M, LI N, et al. Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer[J]. Sci Rep, 2018, 8(1):1188. DOI URL
[14]	唐兴, 蒋东, 赵军. 外周血叶酸受体阳性循环肿瘤细胞检测在非小细胞肺癌筛查中的应用价值[J]. 中华实用诊断与治疗杂志, 2021, 35(3):280-283.
[15]	ZHOU Q, GENG Q, WANG L, et al. Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules:a non-invasive biomarker for predicting malignancy and tumour invasiveness[J]. EBioMedicine, 2019, 41:236-243. DOI URL
[16]	CHEN X, ZHOU F, LI X, et al. Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer[J]. Ann Transl Med, 2020, 8(10):631. DOI URL
[17]	MURPHY A G, FOLEY K, RUCKI A A, et al. Stromal annexin A2 expression is predictive of decreased survival in pancreatic cancer[J]. Oncotarget, 2017, 8(63):106405-106414. DOI URL
[18]	马永峰, 要莉莉, 刘利, 等. NSCLC患者组织中SIRT2、ProGRP、CHCHD2表达情况与临床病理特征及预后的关系[J]. 国际检验医学杂志, 2021, 42(1):75-77.

组别	例数	FR⁺-CTC/（FU/3 mL）	ANXA2/（ng/mL）	ProGRP/（pg/mL）
肺癌组	116	12.15±2.57	33.78±3.67	126.73±17.35
对照组	100	5.41±1.22	18.59±2.83	38.89±6.73
t值		26.765	23.641	19.544
P值		<0.001	<0.001	<0.001

组别	例数	FR⁺-CTC/（FU/3 mL）	ANXA2/（ng/mL）	ProGRP/（pg/mL）
肺癌组	116	12.15±2.57	33.78±3.67	126.73±17.35
对照组	100	5.41±1.22	18.59±2.83	38.89±6.73
t值		26.765	23.641	19.544
P值		<0.001	<0.001	<0.001

项目	AUC（95%CI^①）	最佳临界值	敏感性/%	特异性/%	Youden指数
FR⁺-CTC	0.885（0.833~0.930）	8.70 FU/3 mL	82.1	81.7	63.8
ANXA2	0.810（0.780~0.886）	26.80 ng/mL	72.0	83.0	55.0
ProGRP	0.696（0.608~0.735）	70.50 pg/mL	85.0	60.1	45.1
联合检测	0.935（0.906~0.973）	0.284	90.1	84.5	74.6

项目	AUC（95%CI^①）	最佳临界值	敏感性/%	特异性/%	Youden指数
FR⁺-CTC	0.885（0.833~0.930）	8.70 FU/3 mL	82.1	81.7	63.8
ANXA2	0.810（0.780~0.886）	26.80 ng/mL	72.0	83.0	55.0
ProGRP	0.696（0.608~0.735）	70.50 pg/mL	85.0	60.1	45.1
联合检测	0.935（0.906~0.973）	0.284	90.1	84.5	74.6

指标	CYFRA21-1		NSE		SCC-Ag
指标	r值	P值	r值	P值	r值	P值
FR⁺-CTC	0.691	0.001	0.502	0.008	0.457	0.005
ANXA2	0.710	0.003	0.371	0.009	0.411	0.004
ProGRP	0.568	0.005	0.542	0.007	0.601	0.006